Showing 2 results for Tumor Necrosis Factor-Alpha.
Saedeh Ebrahimi, Saeed Kalantari , Soheil Rahmani Fard , Mitra Kohandel, Zahra Amiri, Yousef Alimohamadi , Sara Minaeian,
Volume 80, Issue 2 (5-2022)
Abstract
Background: Despite the considerable advances in acquired immunodeficiency syndrome (AIDS) treatment and management, finding the cure for this disease has been hindered by emerging challenges such as virus resistance and treatment failures. The purpose of this study is to compare the cytokine profiles of patients with successful treatment and patients with unsuccessful treatment to gain a better understanding of treatment failure mechanisms.
Methods: Sixty-nine human immunodeficiency virus (HIV) positive patients who were referred to the west health center of Tehran between September 2018 and March 2021 were included in this study. Blood CD4+ cell count and viral load was measured using the flow cytometry and quantitative real-time polymerase chain reaction (RT-qPCR) methods respectively. Based on the viral load test results patients were divided into successful treatment (viral load<200 copies/ml, n=36) and unsuccessful treatment (viral load>200 copies/ml, n=33) groups. Subsequently, tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) serum levels were measured using the enzyme-linked immunosorbent assay (ELISA) method.
Results: Analysis of data revealed that there was no difference in demographic data, medical history and clinical laboratory test results between the study groups. Elisa test results showed that serum TNF-α levels were significantly higher in the unsuccessful treatment group compared to the successful treatment group (10.43±10.17 vs 5.37±5.25, P=0.01) but no differences were observed in IL-10 levels between the study groups. Furthermore, age and sex-adjusted linear regression models showed that non-nucleoside reverse-transcriptase inhibitors (NNRTI)-based treatment regimen is positively associated with serum IL-10 levels in patients with unsuccessful treatment (B coefficient 10.88 (95% CI: 1.32-20.45), P=0.03). Moreover, based on the results of the linear regression models, no relationship between HIV viral load and serum IL-10 and TNF-α level was observed.
|
Conclusion: Results of this study showcased the importance of TNF-α in disease progression and treatment failure. Further future studies regarding this relationship can provide vital information in AIDS treatment research.
|
Elham Rajaei , Forough Nokhostin, Maedeh Ekhtelat, Nasrin Masihpour, Maryam Dastoorpour,
Volume 82, Issue 11 (2-2025)
Abstract
Background: Autoimmune inflammatory diseases, which are often associated with severe and chronic complications, affect approximately 7.6-9.4% of world's population. The present study was conducted with the aim of investigating the frequency of ocular side effects of anti-TNF-α drugs in patients with rheumatic diseases.
Methods: In this analytical epidemiological study, 122 patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis who were treated with TNF-α inhibitory drugs (including Infliximab, Adalimumab and Etanercept) referred to Golestan Hospital of Ahvaz, Iran, in 2019-2022 were examined. Ocular complications including anterior uveitis, macular edema, anterior ischemic optic neuropathy, diplopia with paired neurological involvement, anterior uveitis with diplopia and keratitis sicca were evaluated by an ophthalmologist after six months of treatment with TNF-α inhibitory drugs. Infliximab was used on day zero, week two and four, and then every 6 to 8 weeks with a dose of 3 to 5 per kilogram of body weight. Adalimumab dosage was 40 mg every other week and Etanercept was taken at a dose of 50 mg weekly.
Results: From 122 patients, 59 (48.36%) and 36 (29.51%) had rheumatoid arthritis and ankylosing spondylitis, respectively. Among 7.38% of reported ocular complications, anterior uveitis was the most common complication (3.28%). Type of anti-TNF-α drug had no significant correlation with the occurrence of ocular complications and eye complications were mainly observed in patients who used etanercept, but there was no significant difference compared to the other two drugs (P=0.1). The mean duration of disease in patients with and without eye complications was 5.47±4.13 and 3.22±2.58 years, respectively (P=0.03). No significant relationship was observed between the duration of anti-TNF-α drugs use and eye complications (P=0.66).
Conclusion: Given the higher incidence of ocular complications in patients taking etanercept, as well as the significant association between the duration of the disease and the occurrence of ocular complications, monitoring long-term treatment and follow-up of rheumatic patients taking anti-TNF-α drugs is of great importance.
